@FiercePharma: Bayer CEO tells Boston audience that pricing pressure threatens innovation--but U.S. isn't the problem. More | Follow @FiercePharma
> The Canadian state of Ontario has agreed to foot the bill for Johnson & Johnson's ($JNJ) new prostate cancer pill Zytiga. Report
> Lundbeck filed for European approval of its new antidepressant, with plans to file in the U.S. by year's end. Report
> FDA sent Jazz Pharmaceuticals a warning letter, saying that a patient brochure supporting the antipsychotic drug FazaClo was false or misleading because it left out or minimized the drug's risks and overstated its efficacy. Report
> The U.K.'s pharma industry trade group cleared Sanofi ($SNY) of wrongdoing after an ex-employee accused the French drugmaker of promoting drugs for off-label use, among other infractions. Report
> Free trade negotiations between Canada and the E.U. have bogged down in fears that extended patent protections could push up the costs of prescription drugs. Report
> Drug distributor Harvard Drug Group is buying an undisclosed generics manufacturer for $117 million, Standard & Poor's reports. Report
> Glenmark Pharmaceuticals won tentative FDA approval for its version of the Merck ($MRK) migraine treatment Maxalt. Report
@FierceMedDev: We are in the FMD Fierce 15 final stretch. Winners revealed on Oct. 2 at AdvaMed 2012 and in FMD. Innovators all. More | Follow @FierceMedDev
@MarkHFierce: In Mass., Dx, Rx and device companies can now cover modest meals and drinks, thanks to relaxed gift ban regs. Story | Follow @MarkHFierce
@DamianFierce: Seattle startup Innovative Pulmonary has a new CEO and $10.6M in financing. News | Follow @DamianFierce
> Survey: Pharmas value tech when choosing Dx partners. More
> Conflicting arguments abound on the device tax's merits. Item
> Given Imaging soars after filing for Japanese approval. Article
Biotech News
@FierceBiotech: Slideshow: FierceBiotech's 2012 Fierce 15 at BioPharm America 2012. Slideshow | Follow @FierceBiotech
@JohnCFierce: Novartis grabs a $665M option to buy sickle cell disease biotech--Selexys who? Story | Follow @JohnCFierce
@RyanMFierce: MacroGenics banks $20M in potential $1.1B cancer drugs deal with Servier. Article | Follow @RyanMFierce
> NYC coup: Roche picks Big Apple site for new R&D home. News
> Foundation Medicine hauls in $42.5M round to back commercialization effort. Story
> Third Rock bankrolls a new biotech to tackle genetic heart disease. News
Vaccines News
> Cardiff University works on anthrax vaccine for NATO. Item
> Emory snags $6M for HIV/AIDS vaccine research. Article
> Software magnate sinks $104M into vaccine research. More
> Obesity vaccine hits obstacle. Story
Pharma Manufacturing News
> Wholesaler McKesson faces new price-manipulation suit. Story
> Gerresheimer glass plant adds line, new furnace. Article
> Regulators OK Recipharm Monts filling expansion. More
> Florida man tied to cargo thefts ordered to forfeit $55M. News
And Finally... The Congressional Budget Office now estimates that 6 million Americans will pay the penalty for failing to buy health insurance, partly because of higher unemployment. Report